Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(10):665-667; doi:10.1093/jnci/djj220
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Celecoxib Shown Effective in Preventing Colon Polyps

Nancy J. Nelson

The first 10% of the full text of this article appears below.

Celecoxib reduces the occurrence of polyps in the colon and rectum, and it is especially effective in the most difficult patients, two prevention trials have found.

The research is important because it proves that a cyclooxygenase 2 (COX-2) inhibitor like celecoxib can reduce the number of colon and rectal polyps, but the FDA has not approved it to treat those at risk because of fears that the drug will cause heart attacks, strokes, or other cardiac problems.

"We have discovered that COX-2 is a really valid target for trying to prevent the development of tumors, particularly tumors that have a risk of becoming cancerous," said Monica Bertagnolli, M.D., associate professor of surgery at Harvard Medical School in Boston and one of the trials' principal investigators.


Figure Removed (Available Only in the Full Text)
View larger version (138K):
[in this window]
[in a new window]
  		Monica Bertagnolli

 
The studies do not prove that fewer and smaller . . . [Full Text of this Article]

COX-2 Inhibitors as Cancer Prevention

Testing Begins

Causes of Cardiovascular Risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, and J. R. Fay
Targeting the AKT protein kinase for cancer chemoprevention
Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044.
[Abstract] [Full Text] [PDF]